9
Participants
Start Date
August 30, 2023
Primary Completion Date
April 1, 2026
Study Completion Date
October 31, 2030
Intrathalamic AAV.PGRN administration
One-time MRI-guided stereotaxic infusion of AAV.PGRN into the brain
Intrathalamic AVB-101
AVB-101 is made from an adeno-associated virus, serotype 9 (AAV9). AAVs are small viruses that are naturally occurring and do not cause illness or infection on their own. AVB-101 has been modified to contain a copy of the correct (non-mutated) GRN gene, plus some other genetic material to enable the GRN gene to function inside neurons (cells within the brain). AVB-101 has also been modified so that it cannot divide and make new copies of itself (known as 'replication'), which means that it cannot cause disease or a large immune response in your body.
RECRUITING
Vanderbilt University Medical Centre, Nashville
RECRUITING
The Ohio State University (OSU) Wexner Medical Center, Columbus
RECRUITING
Hospital Universitari i Politecnic La Fe, Valencia
RECRUITING
Houston Methodist Hospital, Houston
RECRUITING
Sunnybrook Health Sciences Centre, Toronto
RECRUITING
Amsterdam UMC, Amsterdam
RECRUITING
NEURO-CARE Sp. z o.o. Sp. Komandytowa, Katowice
RECRUITING
Neurologia Slaska Centrum Medyczne, Katowice
RECRUITING
Uniwersyteckie Centrum Kliniczne, SUM w Katowicach, Katowice
RECRUITING
Centrum Medyczne NeuroProtect Sp z o.o., Warsaw
RECRUITING
Mazowiecki Szpital Brodnowski Sp. z o. o., Warsaw
RECRUITING
Skåne University Hospital, Lund
RECRUITING
University College London Hospitals, London
RECRUITING
Euromedis Sp. z o.o., Szczecin
RECRUITING
Hospital Clinic Barcelona, Barcelona
RECRUITING
Cambridge University Hospitals NHS Foundation Trust, Cambridge
RECRUITING
University Hospital of Wales, Cardiff
Lead Sponsor
AviadoBio Ltd
INDUSTRY